Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 431-840-1 | CAS number: 87010-29-5 OXIPROPAZON; OXYPROPAZON
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
3-(3-Hydroxy-propyl)-oxazolidin-2-on is a liquid which is miscible with water. lt has a very low volatility and a log Pow of -1.22.
Evidence for systemic availability of 3-(3-Hydroxy-propyl)-oxazolidin-2-on comes from the subacute toxicity study in rats (BASF AG, 2004). In this study with dietary concentrations of 0, 750, 3000, and 12000 mg/kg feed (corresponding to 0 and about 70, 290 and 1160 mg/kg bw/day), clinico-chemical effects (decreased serum urea in males and females; increased red blood cells and hematocrit in females) were observed at 12000 mg/kg feed. These effects are clear indicators of systemic availability of 3-(3-Hydroxypropyl)-oxazolidin-2on. Since these changes were reversible within a 2-week recovery period, excretion of 3-(3-Hydroxy-propyl)-oxazolidin-2-on and its metabolites appears to be rather rapid.
Considering the chemical structure of 3-(3-Hydroxy-propyl)-oxazolidin-2-on, metabolism may consist of:
-cleavage of the oxazolidinon ring at the ester moiety;
- oxidation of the 3-hydroxy group to the acid via intermediate formation of an aldehyde;
-conjugation of the 3-hydroxy-group.
All potential metabolites of the metabolic pathway described above are more polar and more water soluble than the parent and are expected to be excreted predominantly via the urine.
Studies on genotoxicity (Ames-Test, in vitro cytogenetics) were negative, i.e. there is no indication of a reactivity of 3-(3-Hydroxy-propyl)-oxazolidin-2-on or its metabolites under the test conditions.
Taking into account the low log Pow as well as the results of the 28-day study in rats and the considerations on metabolism, accumulation of 3-(3-Hydroxy-propyl)-oxazolidin-2-on is considered to be unlikely.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
